Axitinib

Metastatic Renal Cell Carcinoma (mRCC) - Pipeline Insight, 2019 by Developmental Stage, Associated Indications, Route of Administration and Molecule Type - ResearchAndMarkets.com

Retrieved on: 
星期五, 二月 22, 2019
Health, Oncology, Pharmaceutical, Cancer, Medicine, MRCC, Medical specialties, Renal cell carcinoma, Metástasis, C-Met, Biotechnology, Sunitinib, Axitinib

The "Metastatic Renal Cell Carcinoma (mRCC) - Pipeline Insight, 2019" drug pipelines has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Metastatic Renal Cell Carcinoma (mRCC) - Pipeline Insight, 2019" drug pipelines has been added to ResearchAndMarkets.com's offering.
  • Metastatic Renal Cell Carcinoma (mRCC) - Pipeline Insight, 2019 offers comprehensive Insight of the pipeline (under development) therapeutics scenario and growth prospects across Metastatic Renal Cell Carcinoma (mRCC) development.
  • The report provides detailed coverage of the pipeline landscape for this mechanism of action, equipped with data from multiple sources with complete pipeline analysis by developmental stage, associated indications, route of administration and molecule type.
  • clinical, pre-clinical and discovery stages for the Metastatic Renal Cell Carcinoma (mRCC)
    The report provides pipeline product profiles which includes product description, developmental activities, licensors & collaborators and chemical information
    Provides pipeline assessment by monotherapy and combination therapy products, stage of development, route of administration, and molecule type for Metastatic Renal Cell Carcinoma (mRCC)
    Identify the relationship between the drugs and use it for target finding, drug repurposing, and precision medicine

FDA Accepts sBLA and Grants Priority Review for BAVENCIO® (avelumab) Plus INLYTA® (axitinib) for the Treatment of Advanced Renal Cell Carcinoma

Retrieved on: 
星期一, 二月 11, 2019
Chemical compounds, Organic compounds, Kidney cancer, Chemistry, Orphan drugs, Pyridines, Breakthrough therapy, Renal cell carcinoma, Axitinib, Avelumab, Ipsen

In December 2017, the FDA granted Breakthrough Therapy Designation for BAVENCIO in combination with INLYTA for treatment-nave patients with advanced RCC.

Key Points: 
  • In December 2017, the FDA granted Breakthrough Therapy Designation for BAVENCIO in combination with INLYTA for treatment-nave patients with advanced RCC.
  • In the US, INLYTA is approved as monotherapy for the treatment of advanced RCC after failure of one prior systemic therapy.
  • In the US, INLYTA is approved for the treatment of advanced renal cell carcinoma (RCC) after failure of one prior systemic therapy.
  • Escudier B, Porta C, Schmidinger M et al Renal cell carcinoma: ESMO clinical practice guidelines for diagnosis, treatment and follow-up.

Asembia Expands Collaboration with Pfizer Oncology

Retrieved on: 
星期四, 四月 19, 2018
Chemistry, Pyridines, Organic chemistry, Health, Pfizer, Pharmacy, Palbociclib, Sunitinib, Crizotinib, Axitinib

FLORHAM PARK, N.J., April 19, 2018 /PRNewswire/ --Asembia members can now gain expanded access to Pfizer Oncology defined distribution oncology products for qualified hospital and health system clients.

Key Points: 
  • FLORHAM PARK, N.J., April 19, 2018 /PRNewswire/ --Asembia members can now gain expanded access to Pfizer Oncology defined distribution oncology products for qualified hospital and health system clients.
  • The new agreement includes Pfizer oncology products: Ibrance (palbociclib), Bosulif (bosutinib), Sutent (sunitinib), Inlyta (axitinib) and Xalkori (crizotinib).
  • "Asembia continues to work closely with Pfizer and all our arrangements to help hospitals and health systems give their patients access to these important medications," said Asembia CEO, Lawrence Irene.
  • Asembia has developed this platform to seamlessly integrate with pharmacy dispensing systems and workflows used by specialty pharmacies across the country.